CAS: 1616385-51-3; 4,5-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-yl)-1H-Pyrazole-3-Carboxamide
该化合物是一种杂交循环化合物,其内含一种与2-苯-1-H-丙酰霉[2,3-b][2-3-B]酸相连的丙烯酰胺核心,具有与2-苯-苯-1H-[23-b][2,3.b] 虫酸酯相联系的聚氨酯,其结构复杂性具有作为药用化学多功能中间体的潜力,特别是在活性酶抑制剂研究中.在双甲酯环上存在二甲基替代品,会增强消毒和电子特性,而苯-丙烯丙烯共聚物则会促进的相互吸附,改善结合性.这一化合物对于其在定向药物发现中的潜在应用具有兴趣,因为它具有平衡的脂性和分子僵硬性,可以优化药用基因特征.对于进一步衍生来说,它是一种适合进一步发展生物活性分子的珍贵的骨架.
- 英文名称4,5-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-yl)-1H-Pyrazole-3-Carboxamide
- 中文名称4,5-二甲基-N-(2-苯基-1H-B[2,3-B]吡啶-5-基)-1H-吡唑-3-甲酰胺
- IUPAC名称4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide
- 其它别名,5-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-yl)-1H-Pyrazole-3-Carboxamide
- CAS编号1616385-51-3
- MFCD编号:MFCD34676446
- EINECS号:885-576-9
- FDA UNII编号:2ROQ545LAG
- 分子式:C19H17N5O分子量:331.38
- 产品CID: 816180
- 产品分类Protein Tyrosine Kinase/RTK → c-Kit | Inhibitors/Agonists → Protease → Tyrosinase
物理性质
MSDS等安全信息
欧盟法规
C&L通报合成工艺路线路线简述
海关参考信息
- 2902200000-苯
2912110000-甲醛
2933310010-吡啶
2924199090-其他无环酰胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2025038767-A1
优先权日:2023-08-14
标 题:Cell-free synthesis platform for synthetically dimierized, clickable fragment antigen-binding (fab) fragments
发明人：THAMES ARIEL; RISCHE CLAYTON; JEWETT MICHAEL; BOCHNER BRUCE
权利人:UNIV NORTHWESTERN
摘要:Disclosed are components, systems, methods, and kits for synthesis of diamerized, clickable antigen binding fragments, such as Fab fragments, and uses thereof. The components, systems, methods, and kits disclosed herein utilize cell-free protein synthesis (CFPS) systems and methods to produce clickable antigen binding fragments.
专利号:US-2024217965-A1
优先权日:2020-04-29
标 题 :Synthesis of heterocyclic compounds
专利号:US-11739088-B2
优先权日:2020-04-29
标题 :Synthesis of heterocyclic compounds
专利号:US-2021340139-A1
优先权日:2020-04-29
标 题 :Synthesis of heterocyclic compounds
专利号:CN-115605460-A
优先权日:2020-04-29
标题:Synthesis of heterocyclic compounds
专利号:EP-4143168-A1
优先权日:2020-04-29
标 题 :Synthesis of heterocyclic compounds
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1. Gebreyohannes YK, Burton EA, Wozniak A, Matusow B, Habets G, Wellens J, Cornillie J, Lin J, Nespi M, Wu G, Zhang C, Bollag G, Debiec-Rychter M, Sciot R, Schöffski P. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. Clin Exp Med. 2019 May;19(2):201-210. doi: 10.1007/s10238-018-0541-2. Epub 2018 Dec 6. 7(9):1343-1350. doi: 10.1001/jamaoncol.2021.2086.合成参考文献
参考文献:10.1007/s11899-024-00737-8
摘要:Farmer I, Radia DH. Systemic Mastocytosis: State of the Art. Curr Hematol Malig Rep. 2024 Oct;19(5):197–207. doi: 10.1007/s11899-024-00737-8.
参考文献:10.1097/aci.0000000000001079
摘要:Costanzo G, Marzio V, Cavaglià E, Paoletti G, Heffler E. New treatments for systemic mastocytosis in 2025. Curr Opin Allergy Clin Immunol. 2025 Aug 01;25(4):277–92. doi: 10.1097/aci.0000000000001079.
📝 需求与反馈
尽可能描述清楚需求与问题信息
